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Abstract 
Review on t(1;14)(p35;q32), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Mature B-cell neoplasms 
Epidemiology 
A t(1;14)(p35;q32) LAPTM5/IGH was found in a 
multiple myeloma cell line (Hayami et al., 2003). 
Two other cases of t(1;14)(p35;q32), but without 
gene assessment were described: a male patient, with 
Binet stage 1 chronic lymphocytic leukemia (CLL), 
and with mutated NOTCH1 (Giudice et al., 2018), 
and a female aged 55-year old female patient with 
follicular lymphoma (Slavutsky et al., 1987). 
Genetics 
To be noted is that a PHC2 (1p35.1) / HSP90AA1 
(14q32.31) fusion was found in prostate cancer 
(Yoshihara et al., 2015) and a PPP2R5C (14q32.31) 
/ CCDC28B (1p35.2) fusion in hepatocellular  
carcinoma (Hu et al., 2018), data extracted from 
http://atlasgeneticsoncology.org/Bands/1p35.html. 
Genes involved and 
proteins 
LAPTM5 (lysosomal protein 
transmembrane 5) 
Location 
1p35.2 
Protein 
262 amino acids, contains 5 trans-membrane helices. 
Membrane protein that localizes to intracellular 
vesicles, lysosomes in particular. LAPTM5 may play 
an important role as a negative regulator of T cell or 
B cell receptor-mediated signaling.  
Overexpression of LAPTM5 induces lysosomal cell 
death. LAPTM5 transcription is often decreased in 
various types of cancer cell lines, in non-small cell 
lung cancer and esophageal squamous cell 
carcinoma tumors.  
Low expression is associated with poor prognosis. 
LAPTM5 functions as a tumor suppressor (Nuylan 
et al., 2016). 
IGH (Immunoglobulin Heavy) 
Location 
14q32.33 
Result of the chromosomal 
anomaly 
del(5q) in acute lymphoblastic leukemia (ALL) Zamecnikova A, al Bahar S 
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Hybrid gene 
Description 
The rearrangement occurred between the switch 
region of IGH and the first intron of LAPTM5. 
LAPTM5 was interrupted within its coding region 
and was not expressed (Hayami et al., 2003). 
Fusion protein 
Oncogenesis 
Inactivation of LAPTM5 
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